Synthetic data only. Never enter patient information; nothing is sent or stored. For clinicians. Not FDA cleared.For licensed clinicians. Educational demonstration on synthetic data. Never enter real patient identifiers or protected health information: everything runs in your browser and nothing is sent or stored. Clinical decision support only; not FDA cleared; physician review is required.
CPE-003 · Progression
PROG-002: Hemodynamically active therapy eGFR change
Hemodynamically active therapy eGFR change. Evaluates hemodynamically active therapy recently initiated or increased is true.
Condition
- All of:
- hemodynamically active therapy recently initiated or increased == true
- percent change eGFR from pretherapy <= -30
What it reports
- Progression flag: therapy_associated_eGFR_decline_requires_evaluation
- Message: A >30% GFR reduction after hemodynamically active therapy warrants evaluation; do not automatically discontinue kidney-protective therapy.
Evidence
- R1KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Disease: Improving Global Outcomes (KDIGO), 2024.Supports: CKD definition and chronicity CGA classification albuminuria confirmation risk prediction referral medication stewardship progression monitoring
Cases where this rule fires
Open a case to see this rule fire with real inputs, then change the values until it stops.
Try Biod in your practice
The Clinical Intelligence Layer — transforming fragmented clinical information into structured intelligence for clinician review and action.